Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Gabapentin Market Grown from 2024 to 2025?

In recent times, the market size of gabapentin has seen significant growth. It is projected to expand from $2.78 billion in 2024 to $3.01 billion in 2025 with a compound annual growth rate (CAGR) of 8.5%. The growth over the historic period can be attributed to factors like the rising prevalence of epilepsy, an increase in the instances of neuropathic pain, heightened societal awareness about neurological disorders, an escalating geriatric population, and an increase in the usage of generic anticonvulsants.

What Growth Rate Is Anticipated for the Gabapentin Market in the Coming Years?

In the following years, the gabapentin market size is forecasted to experience robust growth, with a projection to reach $4.12 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this growth during the forecast period include a growing need for managing chronic pain, increased approvals for gabapentin products, the expansion of healthcare access in emerging areas, a rising emphasis on individualized medicine, and an escalating burden of neurological disorders. Key trends during the forecast period encompass progressions in drug delivery systems, the combination of gabapentin in therapy regimens, technology-led R&D for neuropathic pain, improvements in extended-release formulations, and the evolution of pharmacogenomics applications.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24544&type=smp

Who Are the Leading Companies in the Gabapentin Market?

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

What Are the Key Drivers of the Gabapentin Market?

The escalating incidence of epilepsy is predicted to spur the expansion of the gabapentin market. Known to be a brain complication, epilepsy is often marked by recurrent seizures which are the results of irregular brain electrical activity. The main reason for the increase in epilepsy is the growing number of older adults, as age augments the likelihood of neurological conditions inducing seizures. Gabapentin plays a role in curbing epilepsy by suppressing the abnormal neural activity in the brain and reducing the signals leading to seizures. This is made possible by the medication targeting calcium channels to deter the seizures. For example, the Centers for Disease Control and Prevention, an agency of the US government, reported in May 2024 that roughly 2.9 million U.S. adults aged 18 and over cited living with active epilepsy in 2022, showcasing a rise of 1.08% from the preceding year. Hence, the escalating incidence of epilepsy is fuelling the expansion of the gabapentin market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24544&type=smp

What Are the Key Market Segments in the Gabapentin Industry?

The gabapentin market covered in this report is segmented –

1) By Type: Generic, Branded

2) By Dosage Form: Tablet, Capsule, Oral Solution

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By Application: Epilepsy, Neuropathic Pain, Restless Legs Syndrome, Other Applications

Subsegments:

1) By Generic: Gabapentin Immediate Release (IR), Gabapentin Extended Release (ER), Gabapentin Capsules, Gabapentin Tablets, Gabapentin Oral Solution

2) By Branded: Neurontin, Gralise, Horizant, Other Branded Formulations

What Are the Latest Trends in the Gabapentin Market?

Key players in the gabapentin market are concentrating their efforts on creating improved formulations like bioequivalent tablets. These enhancements aim to increase therapeutic efficiency and offer broader treatment avenues for neurological ailments. Bioequivalent tablets are essentially generic drugs that deliver the exact dosage of the active ingredient into the bloodstream as swiftly and effectively as their branded counterparts, promising comparable safety and therapeutic benefits. For example, Strides Pharma Science Limited, a pharmaceutical entity based in India, unveiled Gabapentin Tablets USP in 600 mg and 800 mg variants in March 2024. These tablets, approved by the United States Food & Drug Administration (USFDA), aim to boost the neurology product range in the US market. This novel gabapentin enriches bioavailability, exact dosing, and patient-friendly usage, facilitating more predictable therapeutic results, enhanced symptom regulation, and added comfort for prolonged therapy. Gabapentin tablets USP, 600 mg in particular, exhibit multifaceted therapeutic potential by effectively handling an array of neurological conditions like neuropathic pain and partial seizures via reliable dosing and established clinical effectiveness.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gabapentin-global-market-report

What Are the Key Regional Markets in the Gabapentin Industry?

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24544

This Report Delivers Insight On:

1. How big is the gabapentin market, and how is it changing globally?

2. Who are the major companies in the gabapentin market, and how are they performing?

3. What are the key opportunities and risks in the gabapentin market right now?

4. Which products or customer segments are growing the most in the gabapentin market?

5. What factors are helping or slowing down the growth of the gabapentin market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model